Several decades of scientific observations followed by years of basic and now clinical research support the notion that the metabolic power of tumor cells can provide the long-desired Achilles' heel of cancer. Yet many questions remain as to what defines the true metabolic makeup of a tumor and whether well-known factors and pathways involved in metabolic signaling act as tumor suppressors or oncogenes. In 'Bedside to Bench', Kıvanç Birsoy, David M. Sabatini and Richard Possemato discuss how retrospective studies of diabetic individuals with pancreatic cancer treated with the antidiabetic drug metformin point to a possible anticancer effect for this drug. Further research will need to discern whether this drug acts at the organismal level or by directly targeting the power plant of tumor cells. In 'Bench to Bedside', Regina M. Young and M. Celeste Simon peruse the complex function of a key metabolic factor that mediates the cell's response to low oxygen levels, often found in tumors. This hypoxia-inducible factor (HIF) comes in two flavors, which can be either tumor promoting or tumor suppressive, depending on the type of cancer. Because of this, the therapeutic use of HIF inhibitors must proceed with caution. Further defining the relationship between metabolic regulation of HIF and tumor progression may open up new diagnostic tools and treatments.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Programmed ROS/CO-releasing nanomedicine for synergetic chemodynamic-gas therapy of cancer
Journal of Nanobiotechnology Open Access 13 June 2019
-
ROS homeostasis and metabolism: a dangerous liason in cancer cells
Cell Death & Disease Open Access 09 June 2016
-
Divergent targets of glycolysis and oxidative phosphorylation result in additive effects of metformin and starvation in colon and breast cancer
Scientific Reports Open Access 22 January 2016
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Ward, P.S. & Thompson, C.B. Cancer Cell 21, 297–308 (2012).
Eng, C., Kiuru, M., Fernandez, M.J. & Aaltonen, L.A. Nat. Rev. Cancer 3, 193–202 (2003).
Dang, L., Jin, S. & Su, S.M. Trends Mol. Med. 16, 387–397 (2010).
Possemato, R. et al. Nature 476, 346–350 (2011).
Jain, M. et al. Science 336, 1040–1044 (2012).
DeBerardinis, R.J., Lum, J.J., Hatzivassiliou, G. & Thompson, C.B. Cell Metab. 7, 11–20 (2008).
Sanli, Y. et al. Ann. Nucl. Med. 26, 345–350 (2012).
Kalaany, N.Y. & Sabatini, D.M. Nature 458, 725–731 (2009).
Seyfried, B.T., Kiebish, M., Marsh, J. & Mukherjee, P. J. Cancer Res. Ther. 5 Suppl 1, S7–S15 (2009).
Broome, J.D. Cancer Treat. Rep. 65 Suppl 4, 111–114 (1981).
Pelicano, H., Martin, D.S., Xu, R.H. & Huang, P. Oncogene 25, 4633–4646 (2006).
Sadeghi, N., Abbruzzese, J.L., Yeung, S.C., Hassan, M. & Li, D. Clin. Cancer Res. 18, 2905–2912 (2012).
Decensi, A. et al. Cancer Prev. Res. (Phila.) 3, 1451–1461 (2010).
Buzzai, M. et al. Cancer Res. 67, 6745–6752 (2007).
Bailey, C.J. & Turner, R.C. N. Engl. J. Med. 334, 574–579 (1996).
Zhou, G. et al. J. Clin. Invest. 108, 1167–1174 (2001).
Shaw, R.J. et al. Proc. Natl. Acad. Sci. USA 101, 3329–3335 (2004).
Clark, R.A. & Pavlis, M. J. Invest. Dermatol. 129, 529–531 (2009).
Hawley, S.A., Gadalla, A.E., Olsen, G.S. & Hardie, D.G. Diabetes 51, 2420–2425 (2002).
Schneider, M.B. et al. Gastroenterology 120, 1263–1270 (2001).
Marin-Valencia, I. et al. Cell Metab. 15, 827–837 (2012).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Birsoy, K., Sabatini, D. & Possemato, R. Untuning the tumor metabolic machine: Targeting cancer metabolism: a bedside lesson. Nat Med 18, 1022–1023 (2012). https://doi.org/10.1038/nm.2870
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.2870
This article is cited by
-
Programmed ROS/CO-releasing nanomedicine for synergetic chemodynamic-gas therapy of cancer
Journal of Nanobiotechnology (2019)
-
ROS homeostasis and metabolism: a dangerous liason in cancer cells
Cell Death & Disease (2016)
-
Divergent targets of glycolysis and oxidative phosphorylation result in additive effects of metformin and starvation in colon and breast cancer
Scientific Reports (2016)
-
The anti-angiogenic effect of dexamethasone in a murine hepatocellular carcinoma model by augmentation of gluconeogenesis pathway in malignant cells
Cancer Chemotherapy and Pharmacology (2016)
-
Targeting mitochondria metabolism for cancer therapy
Nature Chemical Biology (2015)